Abstract
The toxicities of newer targeted therapies are different from those seen with the traditional chemotherapy. Mammalian target of rapamycin (mTOR) inhibitors are evolving into an important class of drugs in oncology, and this class of drugs presents with a variety of different toxicities. Although similar to the toxicities seen in transplantation, these rapamycin analogs have unique side effects when compared to traditional chemotherapy agents. While most of the toxicities are mild, few can be severe and require routine monitoring. Mucositis and rash are the most common side effects. The metabolic toxicities, hyperglycemia, hyperlipidemia, and hypophosphatemia are different from the side effects traditionally seen with chemotherapy. This review will focus on the common toxicities seen with the mTOR inhibitors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281
Raymond E, Alexandre J, Faivre S et al (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22:2336–2347
Atkins MB, Hildalgo M, Stadler WM et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909–918
Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456
O’Donnell A, Faivre S, Burris HA III et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26:1588–1595
Hartford CM, Berk L, Loewry JW et al (2009) A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res 15:1428–1434
Mita MM, Mita AC, Chu QS et al (2008) Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 26:361–367
Mahe E, Morelon E, Lechaton S et al (2005) Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 79:476–482
Sonis S, Treister N, Chawla S, Demetri G, Haluska F (2010) Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 116:210–215
Campistol JM, de Fijter JW, Flechner SM et al (2010) mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant 24:149–156
Fouladi M, Lanningham F, Wu J et al (2007) Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 25:4806–4812
Chuang P, Langone AJ (2007) Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus. Am J Transplant 7:714–717
Morelon E, Stern M, Israël-Biet D et al (2001) Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 72:787–790
Pham PT, Pham PC, Danovitch GM et al (2004) Sirolimus-associated pulmonary toxicity. Transplantation 77:1215–1220
Duran I, Sui LL, Oza AM et al (2004) Characterization of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 42:1875–1880
Aparicio G, Calvo MB, Medina V et al (2009) Comprehensive lung injury pathology induced by mTOR inhibitors. Clin Transl Oncol 11:499–510
Galanis E, Buckner JC, Maurer MJ et al (2005) Phase II trial of temsirolimus (CCI-779) in recurrent Glioblastoma Multiforme: a north central cancer treatment group study. J Clin Oncol 23:5294–5304
Beretta L, Gingras AC, Svitkin YV et al (1996) Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J 15:658–664
Taha C, Liu Z, Jin J et al (1999) Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin. J Biol Chem 274(46):33085–33091
Rizzieri DA, Feldman E, DiPersio JF et al (2008) A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 14:2756–2762
Executive Summary: Standards of Medical Care in Diabetes—2011. Diabetes Care 34:S4–S10
Brattstrom C, Wilczek H, Tyden G et al (1998) Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 65:1272–1274
Gaasbeek A, Meinders AE (2005) Hypophosphatemia: an update on its etiology and treatment. Am J Med 118:1094–1101
Torisel (2010) Package insert. Wyeth Pharmaceuticals, Philadelphia
Afinitor (2010) Package insert. Novartis Pharmaceuticals Corporation, East Hanover
Acknowledgements
Supported in part by the CTRC P30 Cancer Center Support Grant from the National Cancer Institute (CA054174).
Conflict of interest statement
The authors have no financial relationship with or sponsorship to disclose. No original data is being published in this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Soefje, S.A., Karnad, A. & Brenner, A.J. Common toxicities of mammalian target of rapamycin inhibitors. Targ Oncol 6, 125–129 (2011). https://doi.org/10.1007/s11523-011-0174-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11523-011-0174-9